Literature DB >> 10447452

Zolpidem in progressive supranuclear palsy.

A Daniele, E Moro, A R Bentivoglio.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10447452     DOI: 10.1056/NEJM199908123410721

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  21 in total

Review 1.  Recognizing Atypical Parkinsonisms: "Red Flags" and Therapeutic Approaches.

Authors:  Nikolaus R McFarland; Christopher W Hess
Journal:  Semin Neurol       Date:  2017-05-16       Impact factor: 3.420

Review 2.  Progressive supranuclear palsy: clinical features, pathophysiology and management.

Authors:  A Rajput; A H Rajput
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

3.  Current and future treatments in progressive supranuclear palsy.

Authors:  Irene van Balken; Irene Litvan
Journal:  Curr Treat Options Neurol       Date:  2006-05       Impact factor: 3.598

4.  Progressive Supranuclear Palsy and Corticobasal Degeneration.

Authors:  David G Coughlin; Dennis W Dickson; Keith A Josephs; Irene Litvan
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

5.  Progressive Supranuclear Palsy.

Authors:  Lawrence I. Golbe
Journal:  Curr Treat Options Neurol       Date:  2001-11       Impact factor: 3.598

Review 6.  Zolpidem-induced sleepwalking, sleep related eating disorder, and sleep-driving: fluorine-18-flourodeoxyglucose positron emission tomography analysis, and a literature review of other unexpected clinical effects of zolpidem.

Authors:  Romy Hoque; Andrew L Chesson
Journal:  J Clin Sleep Med       Date:  2009-10-15       Impact factor: 4.062

Review 7.  Clinical trials: past, current, and future for atypical Parkinsonian syndromes.

Authors:  Richard M Tsai; Adam L Boxer
Journal:  Semin Neurol       Date:  2014-06-25       Impact factor: 3.420

Review 8.  A Review of Treatment Options for Progressive Supranuclear Palsy.

Authors:  Maria Stamelou; Günter Höglinger
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

9.  Available and future treatments for atypical parkinsonism. A systematic review.

Authors:  Davide Vito Moretti
Journal:  CNS Neurosci Ther       Date:  2018-10-07       Impact factor: 5.243

10.  [Atypical Parkinson syndromes].

Authors:  A Strzelczyk; J C Möller; M Stamelou; A Matusch; W H Oertel
Journal:  Nervenarzt       Date:  2008-10       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.